IberiaBank’s Celldex Therapeutics CLDX Stock Holding History

IberiaBank’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-667	Closed	-$156K	–	152
2013 Q2	$156K	Buy	+667	New	+$131K	0.12%	136

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

IberiaBank's CLDX Position: Q3 2013 in Review

IberiaBank sold out of Celldex Therapeutics (CLDX) in Q3 2013, closing a stake of 667 shares — an estimated $156K sold.

IberiaBank first reported a position in CLDX in Q2 2013 and held it in 1 quarter. The position peaked at $156K in Q2 2013. 150 funds tracked by Wall St. Rank hold CLDX as of Q3 2013.

IberiaBank reported no remaining Celldex Therapeutics position as of Q3 2013 after selling out during the quarter.
IberiaBank sold 667 Celldex Therapeutics shares in Q3 2013, an estimated $156K.
IberiaBank first reported a position in Celldex Therapeutics in Q2 2013 and held it in 1 quarter.
IberiaBank's Celldex Therapeutics position peaked at $156K in Q2 2013.
150 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2013.

Based on IberiaBank's 13F filing for Q3 2013, filed 13 Nov 2013.